Popular
BlogNEW
CompaniesNEW
Finance
Technology
Banking
Information Technology
Oil and Energy
Internet
Mining and Metals
Communications
Real Estate
Biotechnology
Automotive
Medical
Retail
Energy
Aeglea BioTherapeutics Investor Presentation Deck slide image

Aeglea BioTherapeutics Investor Presentation Deck

A half-life of 43-56 days in a 300mg SC format is expected to offer a superior product profile for patients MAINTENANCE DOSING PROFILE SPY001 SC 300 MG CITRATE FREE VEDOLIZUMAB SC 108 MG 20 MM CITRATE SPYRE 4-6 INJECTIONS PER YEAR 26 INJECTIONS PER YEAR M -AM HEND-- HD- am did POTENTIAL FOR SEASONAL DOSING HD CM² Cim EUODP -AMH HD- HDP HD- -lin CMH -C 15
View entire presentation

Product

HomeSearchAccount

Categories

Finance PresentationsTechnology PresentationsBanking PresentationsInformation Technology PresentationsOil and Energy PresentationsInternet PresentationsMining and Metals PresentationsCommunications PresentationsReal Estate PresentationsBiotechnology PresentationsAutomotive PresentationsMedical PresentationsRetail PresentationsEnergy Presentations

Company

InsightsContactSupport

Legal

Terms of ServicePrivacy Policy

Connect

TwitterLinkedInInstagramYouTube